Project Grant R01CA299916
Award Date 8/1/26
Completion Date 7/31/31
Dollars Obligated $699K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90032, USA
Similar Awards
- The National Cancer Institute awarded The University of Chicago $692,063 on September 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to advance early colorectal cancer diagnosis and risk stratification using DNA methylation markers. The funded work develops blood-based biomarkers to detect colorectal cancer and advanced adenomas through cell-free DNA analysis, addressing the gap in sensitivity of existing tools such as MSEPT9, Cologuard, and Shield. The research...
- The National Cancer Institute awarded Augusta University Research Institute, Inc. $395,973 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct the CROSS (Cancer at the Crossroads) project, a population-based epidemiologic study evaluating how area-level social determinants of health impact early-onset colorectal cancer (EOCRC) outcomes. The project integrates Surveillance, Epidemiology, and End Results (SEER) 17 incidence data linked with county...
- The National Cancer Institute awarded the University of Southern California $135,163 on August 4, 2026, under the Cancer Research Manpower program (CFDA 93.398) for Project Grant K99CA293236, a research effort examining epigenetic barriers to stem cell transformation in colorectal cancer. The funded research investigates how the repressive histone modification H3K27ME3 establishes an epigenetic gatekeeping mechanism that restricts stemness programs to intestinal stem cells and how erosion of...
- The National Cancer Institute awarded the University of California, San Diego $671,226 on May 15, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop engineered native bacteria—host-derived E. coli strains—as a microbial platform for durable, targeted delivery of therapeutic molecules to the gut to prevent or treat colorectal cancer. The research addresses a critical gap in microbial therapies for colorectal cancer, which the American Cancer Society projects will account...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded the University of California, Los Angeles $518,451 on June 2, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to leverage multimodal signatures to personalize rectal cancer radiotherapy choice. The project runs through May 31, 2031, with performance based in Los Angeles, California. The research addresses rectal cancer, which comprises...
- The National Institutes of Health National Cancer Institute awarded the University of Southern California $581,548 on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the therapeutic mechanisms of targeting WRN in microsatellite-instable colorectal cancer. The research will delineate mechanisms by which Werner helicase inhibition triggers cell death in MSI colorectal cancer cells and elucidate the immunological effects of that cell death. The work focuses on...
- The National Institutes of Health National Cancer Institute awarded Cedars-Sinai Medical Center $679,353 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the protective role of PYDC5 in colorectal cancer prevention and progression. The research elucidates how PYDC5, a protein expressed in intestinal macrophages, functions as an inhibitor of the AIM2 inflammasome and shapes the tumor immune microenvironment. Preliminary findings show that PYDC5 expression...
- The National Cancer Institute awarded Cedars-Sinai Medical Center $662,610 on April 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate a plasma-based panel of methylated circulating tumor DNA markers for detecting recurrence and predicting therapy response in colorectal cancer patients. The award funds a five-year research collaboration between Cedars-Sinai Medical Center and H. Lee Moffitt Cancer Center and Research Institute to evaluate the...
- The National Cancer Institute awarded the University of Southern California $560,863 on June 2, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of p73-mediated death receptor 5 (DR5) induction in therapeutic response to cyclin-dependent kinase (CDK) inhibition in colorectal cancer. The project examines how CDK inhibitors trigger a signaling cascade in which CDK inhibition leads to p73 dephosphorylation and nuclear translocation, which in turn activates DR5...
- The National Cancer Institute awarded Cold Spring Harbor Laboratory $704,182 under the Cancer Biology Research program (CFDA 93.396) on June 16, 2026, to dissect non-mutational mechanisms driving benign-to-malignant transition in colorectal cancer. The project uses a novel mouse model that stepwise acquires mutations mirroring human colorectal cancer progression—starting with APC knockout to initiate benign polyps, then inducing KRAS G12V and TP53 loss in rare cells within established polyps...